Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 6.67B |
| Revenue (ttm) | 4.06B |
| Net Income (ttm) | 482.20M |
| Shares Out | 60.51M |
| EPS (ttm) | 7.51 |
| PE Ratio | 14.68 |
| Forward PE | 14.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404,501 |
| Open | 111.12 |
| Previous Close | 112.48 |
| Day's Range | 109.56 - 111.12 |
| 52-Week Range | 95.49 - 148.06 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 183.08 (+66.0%) |
| Earnings Date | Jul 30, 2025 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry... [Read more]
Financial Performance
In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $183.08, which is an increase of 66.00% from the latest price.
News
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
– Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN , July 10, 2025 /PRNewswire/ -- Jazz Pharmace...
Is JAZZ Stock Undervalued At $110?
Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commis...
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
In recent months, Jazz Pharmaceuticals plc has remained a stock that has seen some decline in attention from retail investors. This comes amid the potential approval of Zepzelca in combination with Te...
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN , July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Europea...
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in bot...
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analy...
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point o...
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profil...
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and...
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcar...
Jazz Pharmaceuticals: One Step Forward, One Back
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compe...
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and...
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
– Total revenues of $898 million in 1Q25 –– Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca ® in 1L ES-SCLC –– Affir...
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management ...
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ha...
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore po...
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
DUBLIN , April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of...
Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN , April 21, 2025 /PRNewswire/ -- J...
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case
Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
DUBLIN , March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management w...
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia b...
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chime...
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million.
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.